Develops medicines for people with serious blood diseases, including treatments aimed at changing heme production and iron levels to address porphyrias, anemia, polycythemia vera and sickle cell disease.
10-K for FY2025, filed Feb 26, 2026
No revenue reported yet.
10-K for FY2022, filed Mar 31, 2023
10-Q for Q3 FY2026, filed Nov 5, 2026
−$59.5MView ↗
8-K, filed Sep 10, 2026
On September 9, 2026, the Company announced initial results from the RESTORE-PV clinical trial of DISC-3405 in patients with PV. The Phase…View ↗
8-K, filed Feb 27, 2026
On February 26, 2026, the board of directors of Disc Medicine, Inc. (the “Company”) approved, and management began implementing, a…View ↗
Treatment targets
The older report named chronic kidney disease anemia and Diamond-Blackfan anemia among its targets; the latest report names inflammatory bowel disease anemia and sickle cell disease among its current targets.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Feb 26, 2026We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for…View ↗
We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for…View ↗
Competes with Agios Pharmaceuticals, Akebia Therapeutics, Amgen, Astellas Pharma, Bristol-Myers Squibb, FibroGen, GlaxoSmithKline, Incyte, Ono Pharmaceuticals, Keros Therapeutics, Merck &, Otsuka Pharmaceutical, Vifor Pharma, Clinuvel, Mitsubishi Tanabe Pharma, BridgeBio Pharma, Boehringer Ingelheim, Pfizer, Eli Lilly and, and Organon &
10-K for FY2025, filed Feb 26, 2026We face competition more specifically from companies that discover, develop, and market therapies for the treatment of hematologic…View ↗
Loading...